Douglas M. Tollefsen, M.D., Ph.D.

Publications

• Metcalf JA, Ma X, Linders B, Wu S, Schambach A, Ohlemiller KK, Kovacs A, Bigg M, He L, Tollefsen DM, Ponder KP
  A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
  Mol Ther 2009 Oct 20; [Epub ahead of print]
• Tollefsen DM
  Chapter 176S: Antithrombin deficiency.
  In “Scriver’s Online Metabolic and Molecular Bases of Inherited Disease” (Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, eds.), McGraw-Hill, New York, http://www.ommbid.com (2009)
• Werneck CC, Vicente CP, Weinberg JS, Shifren A, Pierce RA, Broekelmann TJ, Tollefsen DM, Mecham RP
  Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury.
  Blood 2008 Apr 15;111(8):4137-44
• He L, Giri TK, Vicente CP, Tollefsen DM
  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.
  Blood 2008 Apr 15;111(8):4118-25
• Church FC, Pike RN, Tollefsen DM, Buckle AM, Ciaccia AV, Olson ST
  Regulation of hemostasis by heparin-binding serpins.
  In “Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity” (Silverman GA, Lomas DA, eds.), World Scientific Publishing Company, London, pp. 509-554 (2007)
• Tollefsen DM
  Heparin cofactor II modulates the response to vascular injury.
  Arterioscler Thromb Vasc Biol 2007 Mar;27(3):454-60
• Vicente CP, He L, Tollefsen DM
  Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.
  Blood 2007 Dec 15;110(13):4261-7
• Tollefsen DM, Zhang L
  Heparin and vascular proteoglycans.
  In “Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th Edition” (Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 271-283 (2006)
• Majerus PW, Tollefsen DM
  Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs.
  In “Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition” (Brunton LL, Lazo JS, Parker KL, eds.), McGraw-Hill, New York, pp. 1467-1488 (2006)
• Halldorsdottir AM, Zhang L, Tollefsen DM
  N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
  Glycobiology 2006 Aug;16(8):693-701
• Giri TK, Tollefsen DM
  Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.
  Blood 2006 Apr 1;107(7):2753-8
• Giri TK, Ahn CW, Wu KK, Tollefsen DM
  Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study.
  Arterioscler Thromb Vasc Biol 2005 Dec;25(12):2689-2690
• Chen HH, Vicente CP, He L, Tollefsen DM, Wun TC
  Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.
  Blood 2005 May 15;105(10):3902-9
• Pomin VH, Pereira MS, Valente AP, Tollefsen DM, Pavao MS, Mourao PA
  Selective cleavage and anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity.
  Glycobiology 2005 Apr;15(4):369-81
• Vicente CP, He L, Pavao MS, Tollefsen DM
  Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
  Blood 2004 Dec 15;104(13):3965-70
• Tollefsen DM
  Does heparin cofactor II modulate atherosclerosis and restenosis?
  Circulation 2004 Jun 8;109(22):2682-4
• He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, Zutter MM
  The contributions of the {alpha}2{beta}1 integrin to vascular thrombosis in vivo.
  Blood 2003 Nov 15;102(10):3652-3657
• Tollefsen DM
  Heparin cofactor.
  In “Wiley Encyclopedia of Molecular Medicine, Volume 3” (Creighton TE, ed.), John Wiley & Sons, New York, pp. 1591-1593 (2002)
• Tollefsen DM
  CAP consensus conference XXXVI: Diagnostic issues in thrombophilia: Heparin cofactor II deficiency.
  Arch Pathol Lab Med 2002 Nov;126(11):1394-400
• Verhamme IM, Olson ST, Tollefsen DM, Bock PE
  Binding of exosite ligands to human thrombIn: Re-evaluation of allosteric linkage between thrombin exosites I and II.
  J Biol Chem 2002 Mar 1;277(9):6788-6798
• He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM
  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
  J Clin Invest 2002 Jan 15;109(2):213-219
• Majerus PW, Tollefsen DM
  Anticoagulant, thrombolytic, and antiplatelet drugs.
  In “Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th Edition” (Hardman JG, Limbird LE, Molinoff PB, Gilman AG, eds.), McGraw-Hill, New York, pp. 1519-1538 (2001)
• Tollefsen DM
  Antithrombin deficiency.
  In “The Metabolic and Molecular Bases of Inherited Disease, 8th Edition” (Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds.), McGraw-Hill, New York, pp. 4455-4471 (2001)
• Broze GJ Jr, Tollefsen DM
  Regulation of blood coagulation by protease inhibitors.
  In “The Molecular Basis of Blood Diseases, 3rd Edition” (Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds.), W. B. Saunders Co., Philadelphia, pp. 657-679 (2001)
• Lian F, He L, Colwell NS, Lollar P, Tollefsen DM
  Anticoagulant activities of amonoclonal antibody that binds to exosite II of thrombin.
  Biochemistry 2001 Jul 24;40(29):8508-13
• Crowther MA, Ginsberg JS, Tollefsen DM, Blinder MA
  Heparin.
  In “Hematology: Basic Principles and Practice, 3rd Edition” (Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds.), Churchill Livingstone, New York, pp. 2046-2056 (2000)
• Maekawa H, Sato H, Tollefsen DM
  Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
  Thromb Res 2000 Dec 1;100(5):443-51
• Colwell NS, Grupe MJ, Tollefsen DM
  Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions.
  Biochim Biophys Acta 1999 Apr 12;1431(1):148-56
• Martin DJ, Toce JA, Anevski PJ, Tollefsen DM, Abendschein DR
  Anticoagulant and antithrombotic activity of maltodapoh, a novel sulfated tetrasaccharide.
  J Pharmacol Exp Ther 1999 Feb;288(2):516-21
• Colwell NS, Tollefsen DM
  Isolation of frog and chicken cDNAs encoding heparin cofactor II.
  Thromb Haemost 1998 Nov;80(5):784-90
• Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM
  Allosteric effects of amonoclonal antibody against thrombin exosite II.
  Biochemistry 1998 Oct 27;37(43):15057-65
• Pavao MS, Aiello KR, Werneck CC, Silva LC, Valente AP, Mulloy B, Colwell NS, Tollefsen DM, Mourao PA
  Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans.
  J Biol Chem 1998 Oct 23;273(43):27848-57
• Han JH, Tollefsen DM
  Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex.
  Biochemistry 1998 Mar 3;37(9):3203-9
• Tollefsen DM
  Heparin cofactor II.
  Adv Exp Med Biol 1997;425:35-44
• Han JH, Cote HC, Tollefsen DM
  Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II.
  J Biol Chem 1997 Nov 7;272(45):28660-5
• Colwell NS, Tollefsen DM, Blinder MA
  Identification of amonoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
  Br J Haematol 1997 Apr;97(1):219-26
• Han JH, Van Deerlin VM, Tollefsen DM
  Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II.
  J Biol Chem 1997 Mar 28;272(13):8243-9
• Majerus PW, Broze GJ Jr, Miletich JP, Tollefsen DM
  Anticoagulant, thrombolytic, and antiplatelet drugs.
  In “The Pharmacological Basis of Therapeutics, 9th Edition” (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds.), McGraw-Hill, New York, pp. 1341-1359 (1996)
• Mourao PA, Pereira MS, Pavao MS, Mulloy B, Tollefsen DM, Mowinckel MC, Abildgaard U
  Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action.
  J Biol Chem 1996 Sep 27;271(39):23973-84
• Maekawa H, Tollefsen DM
  Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes.
  J Biol Chem 1996 Aug 2;271(31):18604-9
• Tollefsen DM
  Insight into the mechanism of action of heparin cofactor II.
  Thromb Haemost 1995 Nov;74(5):1209-14
• Tollefsen DM
  Antithrombin deficiency.
  In “The Metabolic and Molecular Bases of Inherited Disease, 7th Edition” (Scriver CR, Beaudet AL, Sly WS, Valle D, eds.), McGraw-Hill, New York, pp. 3313-3334 (1995; CD-ROM update 1996)
• Tollefsen DM, Blinder MA
  Heparin.
  In “Hematology: Basic Principles and Practice, 2nd Edition” (Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein, LE, eds.), Churchill Livingstone, New York, pp. 1802-1813 (1995)
• Pavao MS, Mourao PA, Mulloy B, Tollefsen DM
  A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity.
  J Biol Chem 1995 Dec 29;270(52):31027-36
• Tollefsen DM
  The interaction of glycosaminoglycans with heparin cofactor II.
  Ann N Y Acad Sci 1994 Apr 18;714:21-31
• Broze GJ Jr, Tollefsen DM
  Regulation of blood coagulation by protease inhibitors.
  In “The Molecular Basis of Blood Diseases, 2nd Edition” (Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds.), W. B. Saunders Co., Philadelphia, pp. 629-656 (1994)
• Sheehan JP, Tollefsen DM, Sadler JE
  Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
  J Biol Chem 1994 Dec 30;269(52):32747-51
• Zhang GS, Mehringer JH, Van Deerlin VM, Kozak CA, Tollefsen DM
  Murine heparin cofactor II: purification, cDNA sequence, expression, and gene structure.
  Biochemistry 1994 Mar 29;33(12):3632-42
• Gebbink RK, Reynolds CH, Tollefsen DM, Mertens K, Pannekoek H
  Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1.
  Biochemistry 1993 Feb 16;32(6):1675-80
• Sheehan JP, Wu Q, Tollefsen DM, Sadler JE
  Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
  J Biol Chem 1993 Feb 15;268(5):3639-45
• Joslin G, Wittwer A, Adams S, Tollefsen DM, August A, Perlmutter DH
  Cross-competition for binding of alpha1-antitrypsin (alpha1 AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified alpha1 AT.
  J Biol Chem 1993 Jan 25;268(3):1886-93
• Tollefsen DM
  Heparin cofactor II.
  In “Human Protein Data” (Haeberli A, ed.), VCH Verlagsgesellschaft mbH, Weinheim (1992; updated 1997)
• Tollefsen DM
  The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
  Adv Exp Med Biol 1992;313:167-76
• Van Deerlin VM, Tollefsen DM
  Molecular interactions between heparin cofactor II and thrombin.
  Semin Thromb Hemost 1992;18(3):341-6
• Tollefsen DM
  Heparin: basic and clinical pharmacology.
  In “Hematology: Basic Principles and Practice” (Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds.), Churchill Livingstone, New York, pp. 1436-1445 (1991)
• Van Deerlin VM, Tollefsen DM
  The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
  J Biol Chem 1991 Oct 25;266(30):20223-31
• Mehringer JH, Weigel CJ, Tollefsen DM
  Cyclic AMP-dependent protein kinase phosphorylates serine378 in vitronectin.
  Biochem Biophys Res Commun 1991 Aug 30;179(1):655-60
• Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC
  Role of lysine 173 in heparin binding to heparin cofactor II.
  J Biol Chem 1991 May 5;266(13):8129-35
• Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM
  Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11.
  Biochemistry 1991 Feb 5;30(5):1350-7
• Majerus PW, Broze GJ Jr, Miletich JP, Tollefsen DM
  Anticoagulant, thrombolytic, and antiplatelet drugs.
  In “The Pharmacological Basis of Therapeutics, 8th Edition” (Gilman AG, Rall TW, Nies AS, Taylor P, eds.), Pergamon Press, New York, pp. 1311-1331 (1990)
• Tollefsen DM
  Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.
  Semin Thromb Hemost 1990 Apr;16(2):162-8
• Tollefsen DM, Sugimori T, Maimone MM
  Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II.
  Semin Thromb Hemost 1990 Oct;16 Suppl:66-70
• Maimone MM, Tollefsen DM
  Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity.
  J Biol Chem 1990 Oct 25;265(30):18263-71
• Tollefsen DM, Weigel CJ, Kabeer MH
  The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379.
  J Biol Chem 1990 Jun 15;265(17):9778-81
• Derechin VM, Blinder MA, Tollefsen DM
  Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
  J Biol Chem 1990 Apr 5;265(10):5623-8
• Blinder MA, Tollefsen DM
  Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
  J Biol Chem 1990 Jan 5;265(1):286-91
• Tollefsen DM, Maimone MM, McGuire EA, Peacock ME
  Heparin cofactor II activation by dermatan sulfate.
  Ann N Y Acad Sci 1989;556:116-22
• Tollefsen DM
  Disorders of hemostasis.
  In “Manual of Medical Therapeutics, 26th Edition” (Dunagan WC, Ridner ML, eds.), Little, Brown and Co., Boston, pp. 326-340 (1989)
• Tollefsen DM
  Heparin cofactor II.
  In “HeparIn: Chemical and Biological Properties, Clinical Applications” (Lane DA, Lindahl U, eds.), Edward Arnold, London, pp. 257-273 (1989)
• Tollefsen DM
  Antithrombin deficiency.
  In “The Metabolic Basis of Inherited Disease, 6th Edition” (Scriver CR, Beaudet AL, Sly WS, Valle D, eds.), McGraw-Hill, New York, pp. 2207-2218 (1989)
• Hortin GL, Tollefsen DM, Benutto BM
  Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II.
  J Biol Chem 1989 Aug 25;264(24):13979-82
• Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM
  Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate.
  J Biol Chem 1989 Mar 25;264(9):5128-33
• Tollefsen DM
  Structure and function of heparin cofactor II.
  ISI Atlas of Science: Biochemistry 1: 19-24 (1988)
• Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P
  Development of the human coagulation system in the healthy premature infant.
  Blood 1988 Nov;72(5):1651-7
• Maimone MM, Tollefsen DM
  Activation of heparin cofactor II by heparin oligosaccharides.
  Biochem Biophys Res Commun 1988 May 16;152(3):1056-61
• Hortin GL, Tollefsen DM, Santoro SA
  Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
  Am J Clin Pathol 1988 Apr;89(4):515-7
• McGuire EA, Peacock ME, Inhorn RC, Siegel NR, Tollefsen DM
  Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin-binding domain.
  J Biol Chem 1988 Feb 5;263(4):1942-5
• Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM
  Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli.
  Biochemistry 1988 Jan 26;27(2):752-9
• Purkerson ML, Tollefsen DM, Klahr S
  N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation.
  J Clin Invest 1988 Jan;81(1):69-74
• Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P
  Development of the human coagulation system in the full-term infant.
  Blood 1987 Jul;70(1):165-72
• McGuire EA, Tollefsen DM
  Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
  J Biol Chem 1987 Jan 5;262(1):169-75
• Tollefsen DM
  Disorders of hemostasis.
  In “Manual of Medical Therapeutics, 25th Edition” (Orland MJ, Saltman RJ, eds.), Little, Brown and Co., Boston, pp. 271-283 (1986)
• Hortin G, Tollefsen DM, Strauss AW
  Identification of two sites of sulfation of human heparin cofactor II.
  J Biol Chem 1986 Dec 5;261(34):15827-30
• Tollefsen DM, Peacock ME, Monafo WJ
  Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II.
  J Biol Chem 1986 Jul 5;261(19):8854-8
• Inhorn RC, Tollefsen DM
  Isolation and characterization of a partial cDNA clone for heparin cofactor II.
  Biochem Biophys Res Commun 1986 May 29;137(1):431-6
• Jaffe EA, Armellino D, Tollefsen DM
  Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line.
  Biochem Biophys Res Commun 1985 Oct 15;132(1):368-74
• Tollefsen DM, Pestka CA
  Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure.
  Blood 1985 Oct;66(4):769-74
• Parker KA, Tollefsen DM
  The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.
  J Biol Chem 1985 Mar 25;260(6):3501-5
• Tollefsen DM, Pestka CA
  Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
  J Clin Invest 1985 Feb;75(2):496-501
• Tollefsen DM
  Activation of heparin cofactor II by heparin and dermatan sulfate.
  Nouv Rev Fr Hematol 1984;26(4):233-7
• Klahr S, Jost RG, Tollefsen D, Clifton, D
  Fever, leukopenia, acute renal failure, and death in a 65-year-old man.
  Am J Med 1984;77:117-124
• Tollefsen DM, Pestka CA, Monafo WJ
  Activation of heparin cofactor II by dermatan sulfate.
  J Biol Chem 1983 Jun 10;258(11):6713-6
• Tollefsen DM, Majerus DW, Blank MK
  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.
  J Biol Chem 1982 Mar 10;257(5):2162-9
• Tollefsen DM, Blank MK
  Detection of a new heparin-dependent inhibitor of thrombin in human plasma.
  J Clin Invest 1981 Sep;68(3):589-96
• Shuman MA, Majerus PW, Tollefsen DM
  Thrombin generation during hemostasis.
  In “First Florence Conference on Hemostasis and Thrombosis” (Neri Serneri GG, Prentice CRM, eds.), Academic Press, New York, pp. 91-101 (1979)
• Maulitz RM, Tollefsen D, Findley L, Dreisin RB
  Roentgenogram of the month. Sudden onset of chest pain in a middle-aged man.
  Chest 1979 Apr;75(4):507-8
• Majerus PW, Tollefsen DM, Shuman MA
  The interaction of platelets with thrombin.
  In “Platelets in Biology and Pathology” (Gordon JL, ed.), Elsevier/North Holland Biomedical Press, New York, pp. 241-260 (1976)
• Tollefsen DM, Majerus PW
  Evidence for a single class of thrombin-binding sites of human platelets.
  Biochemistry 1976 May 18;15(10):2144-9
• Shuman MA, Tollefsen DM, Majerus PW
  The binding of human and bovine thrombin to human platelets.
  Blood 1976 Jan;47(1):43-54
• Tollefsen DM, Jackson CM, Majerus PW
  Binding of the products of prothrombin activation to human platelets.
  J Clin Invest 1975 Jul;56(1):241-5
• Tollefsen DM, Majerus PW
  Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments.
  J Clin Invest 1975 Jun;55(6):1259-68
• Tollefsen DM, Feagler JR, Majerus PW
  The binding of thrombin to the surface of human platelets.
  J Biol Chem 1974 Apr 25;249(8):2646-51
• Tollefsen DM, Feagler JR, Majerus PW
  Induction of the platelet release reaction by phytohemagglutinin.
  J Clin Invest 1974 Jan;53(1):211-8
• Wubbels GG, Tollefsen DM, Meredith RS, Herwaldt LA
  Radical intermediates in photosubstitution reactions of anthraquinones.
  J Am Chem Soc 1973;95:3820-3822